Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Rang în acțiuni #3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Preț acțiune
$81.40
Capitalizare de piață
$5.39B
Schimbare (1 zi)
1.86%
Schimbare (1 an)
205.46%
Țară
US
Tranzacționează Oruka Therapeutics, Inc. (ORKA)

Categorie

Healthcare
Raport P/S pentru Oruka Therapeutics, Inc. (ORKA)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Oruka Therapeutics, Inc., raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Oruka Therapeutics, Inc. din 2005 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 2.08 -96.07%
2006 52.93 -91.38%
2005 614.26 0.00%
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
10.02 -
US
40.55 -
US
4.19 -
AU
10.44 -
NL
4.52 -
BE